Cargando…

Acquisition of resistance to ceftazidime-avibactam during infection treatment in Pseudomonas aeruginosa through D179Y mutation in one of two bla(KPC-2) gene copies without losing carbapenem resistance

Ceftazidime/Avibactam (CAZ/AVI) is frequently used to treat KPC-producing Pseudomonas aeruginosa (KPC-PA) and Enterobacterales. CAZ/AVI resistance is driven by several mechanisms. In P. aeruginosa this mainly occurs through alteration of AmpC, porins, and/or efflux pump overexpression, whereas in En...

Descripción completa

Detalles Bibliográficos
Autores principales: García, Patricia, Brito, Bárbara, Alcalde-Rico, Manuel, Munita, José M., Martínez, Jose R. W., Olivares-Pacheco, Jorge, Quiroz, Valeria, Wozniak, Aniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478442/
https://www.ncbi.nlm.nih.gov/pubmed/36118031
http://dx.doi.org/10.3389/fcimb.2022.981792
_version_ 1784790573370048512
author García, Patricia
Brito, Bárbara
Alcalde-Rico, Manuel
Munita, José M.
Martínez, Jose R. W.
Olivares-Pacheco, Jorge
Quiroz, Valeria
Wozniak, Aniela
author_facet García, Patricia
Brito, Bárbara
Alcalde-Rico, Manuel
Munita, José M.
Martínez, Jose R. W.
Olivares-Pacheco, Jorge
Quiroz, Valeria
Wozniak, Aniela
author_sort García, Patricia
collection PubMed
description Ceftazidime/Avibactam (CAZ/AVI) is frequently used to treat KPC-producing Pseudomonas aeruginosa (KPC-PA) and Enterobacterales. CAZ/AVI resistance is driven by several mechanisms. In P. aeruginosa this mainly occurs through alteration of AmpC, porins, and/or efflux pump overexpression, whereas in Enterobacterales it frequently occurs through D179Y substitution in the active site of KPC enzyme. This aminoacid change abolishes AVI binding to the KPC active site, hence inhibition is impaired. However, this substitution also decreases KPC-mediated resistance to carbapenems (“see-saw” effect). The goal of this work was to characterize the in vivo acquisition of CAZ/AVI resistance through D179Y substitution in a KPC-PA isolated from a hospitalized patient after CAZ/AVI treatment. Two KPC-PA isolates were obtained. The first isolate, PA-1, was obtained before CAZ/AVI treatment and was susceptible to CAZ/AVI. The second isolate, PA-2, was obtained after CAZ/AVI treatment and exhibited high-level CAZ/AVI resistance. Characterization of isolates PA-1 and PA-2 was performed through short and long-read whole genome sequencing analysis. The hybrid assembly showed that PA-1 and PA-2A had a single plasmid of 54,030 bp, named pPA-1 and pPA-2 respectively. Each plasmid harbored two copies of the bla (KPC)-containing Tn4401b transposon. However, while pPA-1 carried two copies of bla (KPC-2), pPA-2 had one copy of bla (KPC-2) and one copy of bla (KPC-33), the allele with the D179Y substitution. Interestingly, isolate PA-2 did not exhibit the “see-saw” effect. The bla (KPC-33) allele was detected only through hybrid assembly using a long-read-first approach. The present work describes a KPC-PA isolate harboring a plasmid-borne CAZ/AVI resistance mechanism based on two copies of bla (KPC-2)-Tn4401b and D179Y mutation in one of them, that is not associated with loss of resistance to carbapenems. These findings highlight the usefulness of a fine-tuned combined analysis of short and long-read data to detect similar emerging resistance mechanisms.
format Online
Article
Text
id pubmed-9478442
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94784422022-09-17 Acquisition of resistance to ceftazidime-avibactam during infection treatment in Pseudomonas aeruginosa through D179Y mutation in one of two bla(KPC-2) gene copies without losing carbapenem resistance García, Patricia Brito, Bárbara Alcalde-Rico, Manuel Munita, José M. Martínez, Jose R. W. Olivares-Pacheco, Jorge Quiroz, Valeria Wozniak, Aniela Front Cell Infect Microbiol Cellular and Infection Microbiology Ceftazidime/Avibactam (CAZ/AVI) is frequently used to treat KPC-producing Pseudomonas aeruginosa (KPC-PA) and Enterobacterales. CAZ/AVI resistance is driven by several mechanisms. In P. aeruginosa this mainly occurs through alteration of AmpC, porins, and/or efflux pump overexpression, whereas in Enterobacterales it frequently occurs through D179Y substitution in the active site of KPC enzyme. This aminoacid change abolishes AVI binding to the KPC active site, hence inhibition is impaired. However, this substitution also decreases KPC-mediated resistance to carbapenems (“see-saw” effect). The goal of this work was to characterize the in vivo acquisition of CAZ/AVI resistance through D179Y substitution in a KPC-PA isolated from a hospitalized patient after CAZ/AVI treatment. Two KPC-PA isolates were obtained. The first isolate, PA-1, was obtained before CAZ/AVI treatment and was susceptible to CAZ/AVI. The second isolate, PA-2, was obtained after CAZ/AVI treatment and exhibited high-level CAZ/AVI resistance. Characterization of isolates PA-1 and PA-2 was performed through short and long-read whole genome sequencing analysis. The hybrid assembly showed that PA-1 and PA-2A had a single plasmid of 54,030 bp, named pPA-1 and pPA-2 respectively. Each plasmid harbored two copies of the bla (KPC)-containing Tn4401b transposon. However, while pPA-1 carried two copies of bla (KPC-2), pPA-2 had one copy of bla (KPC-2) and one copy of bla (KPC-33), the allele with the D179Y substitution. Interestingly, isolate PA-2 did not exhibit the “see-saw” effect. The bla (KPC-33) allele was detected only through hybrid assembly using a long-read-first approach. The present work describes a KPC-PA isolate harboring a plasmid-borne CAZ/AVI resistance mechanism based on two copies of bla (KPC-2)-Tn4401b and D179Y mutation in one of them, that is not associated with loss of resistance to carbapenems. These findings highlight the usefulness of a fine-tuned combined analysis of short and long-read data to detect similar emerging resistance mechanisms. Frontiers Media S.A. 2022-09-02 /pmc/articles/PMC9478442/ /pubmed/36118031 http://dx.doi.org/10.3389/fcimb.2022.981792 Text en Copyright © 2022 García, Brito, Alcalde-Rico, Munita, Martínez, Olivares-Pacheco, Quiroz and Wozniak https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
García, Patricia
Brito, Bárbara
Alcalde-Rico, Manuel
Munita, José M.
Martínez, Jose R. W.
Olivares-Pacheco, Jorge
Quiroz, Valeria
Wozniak, Aniela
Acquisition of resistance to ceftazidime-avibactam during infection treatment in Pseudomonas aeruginosa through D179Y mutation in one of two bla(KPC-2) gene copies without losing carbapenem resistance
title Acquisition of resistance to ceftazidime-avibactam during infection treatment in Pseudomonas aeruginosa through D179Y mutation in one of two bla(KPC-2) gene copies without losing carbapenem resistance
title_full Acquisition of resistance to ceftazidime-avibactam during infection treatment in Pseudomonas aeruginosa through D179Y mutation in one of two bla(KPC-2) gene copies without losing carbapenem resistance
title_fullStr Acquisition of resistance to ceftazidime-avibactam during infection treatment in Pseudomonas aeruginosa through D179Y mutation in one of two bla(KPC-2) gene copies without losing carbapenem resistance
title_full_unstemmed Acquisition of resistance to ceftazidime-avibactam during infection treatment in Pseudomonas aeruginosa through D179Y mutation in one of two bla(KPC-2) gene copies without losing carbapenem resistance
title_short Acquisition of resistance to ceftazidime-avibactam during infection treatment in Pseudomonas aeruginosa through D179Y mutation in one of two bla(KPC-2) gene copies without losing carbapenem resistance
title_sort acquisition of resistance to ceftazidime-avibactam during infection treatment in pseudomonas aeruginosa through d179y mutation in one of two bla(kpc-2) gene copies without losing carbapenem resistance
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478442/
https://www.ncbi.nlm.nih.gov/pubmed/36118031
http://dx.doi.org/10.3389/fcimb.2022.981792
work_keys_str_mv AT garciapatricia acquisitionofresistancetoceftazidimeavibactamduringinfectiontreatmentinpseudomonasaeruginosathroughd179ymutationinoneoftwoblakpc2genecopieswithoutlosingcarbapenemresistance
AT britobarbara acquisitionofresistancetoceftazidimeavibactamduringinfectiontreatmentinpseudomonasaeruginosathroughd179ymutationinoneoftwoblakpc2genecopieswithoutlosingcarbapenemresistance
AT alcaldericomanuel acquisitionofresistancetoceftazidimeavibactamduringinfectiontreatmentinpseudomonasaeruginosathroughd179ymutationinoneoftwoblakpc2genecopieswithoutlosingcarbapenemresistance
AT munitajosem acquisitionofresistancetoceftazidimeavibactamduringinfectiontreatmentinpseudomonasaeruginosathroughd179ymutationinoneoftwoblakpc2genecopieswithoutlosingcarbapenemresistance
AT martinezjoserw acquisitionofresistancetoceftazidimeavibactamduringinfectiontreatmentinpseudomonasaeruginosathroughd179ymutationinoneoftwoblakpc2genecopieswithoutlosingcarbapenemresistance
AT olivarespachecojorge acquisitionofresistancetoceftazidimeavibactamduringinfectiontreatmentinpseudomonasaeruginosathroughd179ymutationinoneoftwoblakpc2genecopieswithoutlosingcarbapenemresistance
AT quirozvaleria acquisitionofresistancetoceftazidimeavibactamduringinfectiontreatmentinpseudomonasaeruginosathroughd179ymutationinoneoftwoblakpc2genecopieswithoutlosingcarbapenemresistance
AT wozniakaniela acquisitionofresistancetoceftazidimeavibactamduringinfectiontreatmentinpseudomonasaeruginosathroughd179ymutationinoneoftwoblakpc2genecopieswithoutlosingcarbapenemresistance